Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient in Parkinson’s disease.

2006 Report: Medicines in development for neurological disorders. http://www.phrma.org/files/Neurologic_2006.pdf. Published 2006

Reference

Title
2006 Report: Medicines in development for neurological disorders
Publisher
PhRMA
Publication Date
Published 2006
Authors
PhRMA
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • Delaying the onset of Alzheimer’s by only 5 years could reduce the number of people with Alzheimer’s by almost 50% after 50 years.  
  • 91 medicines are currently in development for Alzheimer’s disease.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 out-of-pocket costs for individuals and families dealing with the…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…